Lupi, Laura
 Distribuzione geografica
Continente #
NA - Nord America 610
EU - Europa 266
AS - Asia 261
OC - Oceania 3
AF - Africa 1
SA - Sud America 1
Totale 1.142
Nazione #
US - Stati Uniti d'America 606
HK - Hong Kong 90
SG - Singapore 69
CN - Cina 59
IT - Italia 55
DE - Germania 54
FI - Finlandia 41
TR - Turchia 30
RU - Federazione Russa 26
UA - Ucraina 26
GB - Regno Unito 22
IE - Irlanda 20
IN - India 9
CZ - Repubblica Ceca 8
AU - Australia 3
FR - Francia 3
CA - Canada 2
SA - Arabia Saudita 2
SE - Svezia 2
SI - Slovenia 2
AR - Argentina 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
CH - Svizzera 1
EE - Estonia 1
EG - Egitto 1
ID - Indonesia 1
JM - Giamaica 1
NL - Olanda 1
PA - Panama 1
PK - Pakistan 1
PL - Polonia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 1.142
Città #
Hong Kong 90
Chandler 89
Fairfield 68
Ashburn 62
Singapore 55
Helsinki 39
Princeton 33
Woodbridge 31
New York 29
Wilmington 28
Istanbul 27
Beijing 22
Cambridge 22
Jacksonville 22
Dublin 20
Seattle 20
Shanghai 19
Moscow 16
Houston 15
Romola 12
Munich 9
Brescia 8
Brno 8
Ann Arbor 7
Frankfurt am Main 7
Los Angeles 7
Lancaster 6
Prevalle 5
Des Moines 4
Kilburn 4
Milan 4
Pune 4
San Diego 4
Washington 4
Brindisi 3
Nanchang 3
Soncino 3
Chennai 2
Falkenstein 2
Gavardo 2
Jinan 2
Ljubljana 2
Melbourne 2
Nanjing 2
Padova 2
Prescot 2
Riyadh 2
Rome 2
Venice 2
West Jordan 2
Acton 1
Boardman 1
Bratislava 1
Brussels 1
Buenos Aires 1
Cairo 1
Canberra 1
Castegnato 1
Catania 1
Chaozhou 1
Chiswick 1
Chongqing 1
Espoo 1
Fuzhou 1
Gunzenhausen 1
Hanover 1
Hebei 1
Islamabad 1
Islington 1
Jiaxing 1
Lanzhou 1
Leipzig 1
Nashville 1
New Bedfont 1
Norwalk 1
Ottawa 1
Redmond 1
San Francisco 1
San Mateo 1
Santa Clara 1
Sarajevo 1
Strasbourg 1
Taiyuan 1
Tallinn 1
Tianjin 1
Toronto 1
Wandsworth 1
Warsaw 1
Zurich 1
Totale 874
Nome #
Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial) 114
Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy 84
[Chronic heart failure therapy: where we are and where we are going to] 73
Implications for the Care of Patients with COVID-19 and Inflammatory Myocardial Disease-Reply 63
Prognostic Impact of Heart Failure History in Patients with Secondary Mitral Regurgitation Treated by MitraClip 62
ACE2 down-regulation may contribute to the increased thrombotic risk in COVID-19 58
Impact of disproportionate secondary mitral regurgitation in patients undergoing edge-to-edge percutaneous mitral valve repair 57
COAPT-Like Profile Predicts Long-Term Outcomes in Patients With Secondary Mitral Regurgitation Undergoing MitraClip Implantation 55
Atrial fibrillation in the COVID-19 era: Simple bystander or marker of increased risk? 49
Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) 48
Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure 47
A Score to Assess Mortality After Percutaneous Mitral Valve Repair 45
Changes in Right Ventricular-to-Pulmonary Artery Coupling After Transcatheter Edge-to-Edge Repair in Secondary Mitral Regurgitation 36
Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis 34
Percutaneous Edge-to-Edge Mitral Valve Repair: Beyond the Left Heart 34
Impact of COVID-2019 outbreak on prevalence, clinical presentation and outcomes of ST-elevation myocardial infarction 32
Predictors of optimal procedural result after transcatheter edge-to-edge mitral valve repair in secondary mitral regurgitation 29
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 27
Use of edge-to-edge percutaneous mitral valve repair for severe mitral regurgitation in cardiogenic shock: A multicenter observational experience (MITRA-SHOCK study) 27
Left atrial volume index and outcome after transcatheter edge-to-edge valve repair for secondary mitral regurgitation 24
Prognostic value of right ventricular longitudinal strain in patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge mitral valve repair 23
Impact on clinical outcomes of right ventricular response to percutaneous correction of secondary mitral regurgitation 23
Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation and its impact on mortality 22
High troponin levels in patients hospitalized for coronavirus disease 2019: a maker or a marker of prognosis? 21
Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan 19
Outcome and Morphofunctional Changes on Cardiac Magnetic Resonance in Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination 18
Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study 16
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 14
Prediction of Mortality and Heart Failure Hospitalization After Transcatheter Tricuspid Valve Interventions: Validation of TRISCORE 11
Left atrial strain importance in atrial fibrillation screening process 9
Totale 1.174
Categoria #
all - tutte 11.540
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.540


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202035 0 0 0 0 0 0 3 4 3 7 12 6
2020/2021169 3 6 5 17 5 8 54 12 18 16 19 6
2021/2022134 4 29 5 2 3 12 5 8 4 14 14 34
2022/2023220 18 15 1 10 23 54 4 27 48 0 8 12
2023/2024311 21 5 31 20 20 60 16 12 72 8 3 43
2024/2025237 3 5 19 71 38 60 41 0 0 0 0 0
Totale 1.174